A Phase 3 interventional study of placebo and pregabalin and pramipexol in Idiopathic Restless Legs Syndrome, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.. Completed at 110 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-01-26.
Sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (part of Viatris Inc.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 107 studies in Restless Legs Syndrome with a site in United States — 9 open to participants now, 13 under way, none of them phase 3. Restless Legs Syndrome · United States.
Among the 107 studies in Restless Legs Syndrome with a site in United States, this one is the 5th largest by enrollment of the 95 interventional ones that give a count, is one of 6 that started in 2008, is one of 18 in phase 3, and was the 33rd registered.
259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.
Browse Restless Legs Syndrome studies →9 of the 107 studies in Restless Legs Syndrome with a site in United States are open now. Recruiting first, the newest first:
Noctrix Health, Inc. · Sites in United States
Ages 21+
Rhode Island Hospital · Sites in United States
Ages 18+ · Women only
University of Alabama at Birmingham · Sites in United States
Ages 18+ · Healthy volunteers
HBC Immunology Inc · Sites in United States
Ages 18–60
Stanford University · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
107 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 23 · Phase 3 21 · Phase 4 18
First in 1995; this study’s year is marked. 6 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 731 is above the median of 53 across 200 interventional studies indexed under Restless Legs Syndrome.
Median enrollment 46 across the 95 interventional studies, 72 across the 12 observational. Of the 83 that completed or were terminated, 35 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 107 have an industry lead sponsor. The 10 most frequent:
This study is registered under Pfizer's Upjohn has merged with Mylan to form Viatris Inc., one of the names counted as Viatris Inc.. Under that name alone:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. is the lead sponsor of 434 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 8 (89%) have results posted.
Viatris Inc. has 4 studies filed under Restless Legs Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Restless Legs Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02670161Endeavor HealthQuality Improvement and Practice Based Research in Neurology Using the EMR | 2026-12 |
| NCT07675109Noctrix Health, Inc.Optimizing Extended-Duration (XD-) TOMAC Therapy for Restless Legs Syndrome (RLS) | 2026-12 |
| NCT07061470Hugo W. Moser Research Institute at Kennedy Krieger, Inc.A Clinical Trial of Iron Supplementation for Youth With ADHD and Restless Sleep | 2027-07-31 |
Add all 3 to your calendar (.ics) → With an account.
Among the 107 studies in Restless Legs Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This purpose of this study is to investigate the efficacy and tolerability of pregabalin in treating idiopathic RLS patients for up to 12 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Drug: placebo and pregabalin
Drug: pramipexol
Drug: pramipexol
Drug: Pregabalin
Drug: pramipexol
Drug: pramipexol
following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
Also known as: Lyrica
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Also known as: Mirapex
following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
Also known as: Mirapex
pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Also known as: Lyrica
pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Also known as: Mirapex
pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
Also known as: Mirapex
Restless Legs Syndrome (RLS) Symptom Severity
International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Time frame: Baseline
Change From Baseline in the RLS Symptom Severity at Week 12
IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
Time frame: Baseline, Week 12
Percentage of Participants Responding to Treatment at Week 12
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".
Time frame: Week 12
Percentage of Participants With Augmentation
Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
Time frame: Baseline up to Week 52
Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO)
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
Time frame: Baseline
Change From Baseline in SSQ: Subjective WASO at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
Time frame: Baseline, Week 12
Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.
Time frame: Week 12
Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.
Time frame: Week 12
RLS-Next Day Impact (RLS-NDI)
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
Time frame: Baseline
Change From Baseline in RLS-NDI at Week 12
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
Time frame: Baseline, Week 12
Limb Pain-Visual Analog Scale (Limb Pain-VAS)
100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.
Time frame: Baseline
Change From Baseline in Limb Pain-VAS at Week 12
100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.
Time frame: Baseline, Week 12
Severity of Augmentation Symptoms at Week 12
ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
Time frame: Week 12
Clinical Global Impressions-Severity (CGI-S) at Week 12
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.
Time frame: Week 12
Medical Outcomes Study-Sleep Scale (MOS-SS) at Week 12
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.
Time frame: Week 12
Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.
Time frame: Week 12
Profile of Mood State (POMS) at Week 12
POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.
Time frame: Week 12
Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12
RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.
Time frame: Week 12
Medical Outcomes Study-Short Form 36 (SF-36) at Week 12
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.
Time frame: Week 12
Work Productivity and Activity Impairment Questionnaire: Specific Health Problem (WPAI-SHP) at Week 12
WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.
Time frame: Week 12
| Milestone | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo to Pregabalin 300 mg | Placebo to Pramipexole 0.25 mg | Placebo to Pramipexole 0.5 mg |
|---|---|---|---|---|---|---|
| Started | 185 | 183 | 182 | 61 | 59 | 61 |
| Treated | 182 | 178 | 180 | 59 | 59 | 61 |
| Completed | 93 | 82 | 89 | 32 | 29 | 29 |
| Not completed | 92 | 101 | 93 | 29 | 30 | 32 |
| Withdrew: Death | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Did not meet entrance criteria | 4 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 5 | 18 | 13 | 4 | 8 | 7 |
| Withdrew: Lost to follow-up | 8 | 15 | 8 | 2 | 6 | 6 |
| Withdrew: Withdrawal by subject | 14 | 17 | 9 | 2 | 5 | 3 |
| Withdrew: Other | 3 | 6 | 8 | 2 | 0 | 4 |
| Withdrew: Protocol violation | 6 | 9 | 9 | 0 | 2 | 3 |
| Withdrew: Adverse event | 52 | 35 | 44 | 17 | 9 | 9 |
International Restless Legs Syndrome Study Group Rating Scale (IRLS) is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Restless Legs Syndrome (RLS) Symptom Severity | 22.30 ± 5.73 | 22.40 ± 5.37 | 22.10 ± 5.19 | 22.40 ± 5.58 |
IRLS is psychometrically and clinically valid and reliable clinician-administered instrument used to assess the severity of RLS. It assesses RLS symptom severity and impact on daily living and is comprised of 10 items, scored on 0 to 4 scale, where lower score indicates lower symptom severity/impact on living. Two subscale scores are symptom severity (6 items) ranging from 0-24 (lower score indicates lower symptom severity) and impact on daily living (3 items) ranging from 0-12 (lower score indicates lower impact on living). Item 3 is unrelated to the other items. The global score is calculated from all 10 items, range from 0 to 40, where lower scores reflect lower severity and better quality of life.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in the RLS Symptom Severity at Week 12 | -11.80 ± 0.47 | -7.90 ± 0.49 | -10.50 ± 0.47 | -7.30 ± 0.48 |
CGI-I: 7-point clinician rated scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved), 2 (much improved), or 3 (minimally improved) on the scale. Higher score = more affected. Responders were defined as participants who report CGI-I score of "very much improved" or "much improved".
| Percentage of participants | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Percentage of Participants Responding to Treatment at Week 12 | 71.40 | 51.20 | 62.70 | 46.80 |
Augmentation was worsening of RLS symptoms, attributable to a specific long-term therapeutic intervention for RLS. Percentage of participants with augmentation was evaluated by centralized evaluation board using a set of assessment criteria for potential augmentation which included structured interview for diagnosis of augmentation during RLS treatment (SIDA-RLS), augmentation severity rating scale (ASRS), clinical judgment. ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
| Percentage of participants | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg |
|---|---|---|---|
| Percentage of Participants With Augmentation | 1.70 | 6.60 | 9.00 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
| minutes | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Subjective Sleep Questionnaire (SSQ): Subjective Waking After Sleep Onset (WASO) | 90.60 ± 76.10 | 100.20 ± 85.92 | 83.90 ± 77.35 | 79.50 ± 69.85 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). WASO is time spent awake from sleep onset to final awakening. Total WASO subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Total WASO subscale score ranges from 0-1440 minutes. Lower value indicates better sleep.
| minutes | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in SSQ: Subjective WASO at Week 12 | -49.86 ± 3.06 | -33.69 ± 3.15 | -37.18 ± 3.04 | -32.61 ± 3.10 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Latency subscale (in minutes): numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Latency subscale score ranges from 0-840 minutes. Lower value indicates better sleep.
| minutes | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Subjective Sleep Questionnaire (SSQ): Latency Subscale Score at Week 12 | 41.60 ± 35.76 | 43.10 ± 35.84 | 35.90 ± 33.08 | 47.70 ± 44.89 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Hours of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Hours of sleep subscale score ranges from 0-16 hours. Higher value indicates better sleep.
| hours | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Subjective Sleep Questionnaire (SSQ): Hours of Sleep Subscale Score at Week 12 | 7.00 ± 1.05 | 6.70 ± 1.19 | 6.80 ± 1.09 | 6.70 ± 1.16 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Number of awakenings subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Number of awakenings subscale score ranges from 0-30. Lower value indicates better sleep.
| awakenings | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Subjective Sleep Questionnaire (SSQ): Number of Awakenings Subscale Score at Week 12 | 1.10 ± 1.14 | 1.70 ± 1.22 | 1.50 ± 1.08 | 1.80 ± 2.14 |
SSQ: Participant-rated instrument used to assess previous night's sleep profile. It is used to measure sleep quantity and quality and is comprised of 5 items yielding 5 subscale scores: latency (1 item), hours of sleep (1 item), number of awakenings (1 item), total WASO (1 item), quality of sleep (1 item). Quality of sleep subscale: numerical rating completed by the participant 30 minutes after waking; recall period is the night before. Quality of sleep subscale score ranges from 0-100. Higher score indicates better quality of sleep.
| Units on a scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Subjective Sleep Questionnaire (SSQ): Quality of Sleep Subscale Score at Week 12 | 66.50 ± 20.00 | 57.40 ± 19.83 | 60.20 ± 19.43 | 57.70 ± 20.27 |
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| RLS-Next Day Impact (RLS-NDI) | 49.30 ± 22.03 | 51.90 ± 18.62 | 58.40 ± 20.27 | 50.00 ± 22.64 |
The RLS-NDI is a participant-rated instrument designed to assess daytime performance as related to RLS and the participant's previous night's sleep. The instrument consists of 14 items that encompass 5 domains: tiredness; emotional functioning; social functioning; cognitive functioning; and activities of daily living. There is also 1 global item assessing overall well -being. Each item is scored on a 0-10 numeric rating scale. Total score is the sum of scores from question 1 to 14. The total score ranges from 0 to 140 where higher scores indicate a more severe impact.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in RLS-NDI at Week 12 | -8.10 ± 2.88 | -4.30 ± 2.65 | -14.50 ± 2.50 | -6.60 ± 2.68 |
100 millimeter (mm) line (Visual Analog Scale) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain.
| mm | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Limb Pain-Visual Analog Scale (Limb Pain-VAS) | 4.20 ± 2.70 | 4.30 ± 2.58 | 4.00 ± 2.53 | 4.10 ± 2.52 |
100 mm line (VAS) marked by participant. Intensity of pain range (over past week): 0 mm = no pain to 100 mm = worst possible pain. Change = observation mean minus baseline mean.
| mm | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Change From Baseline in Limb Pain-VAS at Week 12 | -3.20 ± 0.20 | -2.64 ± 0.20 | -2.75 ± 0.21 | -2.20 ± 0.20 |
ASRS measures severity of augmentation and consist of three items to be completed by clinician. Clinician would score participants' answers by comparing post-baseline evaluations to those at baseline. ASRS total score range: 0-24, with higher score indicating more severe augmentation.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Severity of Augmentation Symptoms at Week 12 | 0.90 ± 1.60 | 1.60 ± 2.29 | 1.30 ± 1.87 | 1.40 ± 1.95 |
CGI-S: 7-point clinician rated scale to assess severity of participant's current illness state; range: 1 (normal-not ill at all) to 7 (among the most extremely ill participants). Higher score = more affected.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Clinical Global Impressions-Severity (CGI-S) at Week 12 | 2.90 ± 1.18 | 3.50 ± 1.22 | 3.10 ± 1.17 | 3.70 ± 1.17 |
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Sleep adequacy data was reported at week 12 and not for first 12 weeks (average). Subscale scores range: 0-100; exception quantity of sleep (range 0-24 hours). With exception of sleep quantity and sleep adequacy, higher scores reflect poorer sleep outcomes.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Sleep disturbance (n = 175, 169, 178, 171) | 30.50 ± 21.84 | 39.30 ± 23.72 | 34.40 ± 20.89 | 38.60 ± 21.43 |
| Snoring (n = 172, 169, 178, 170) | 29.00 ± 27.50 | 25.80 ± 28.46 | 25.80 ± 25.81 | 24.60 ± 24.57 |
| Awakening short of breath (n = 175, 169, 178, 171) | 10.50 ± 15.78 | 12.30 ± 17.09 | 13.80 ± 18.22 | 9.60 ± 15.13 |
| Sleep adequacy (n = 128, 120, 133, 125 ) | 61.30 ± 28.57 | 54.80 ± 29.45 | 55.20 ± 27.87 | 50.00 ± 28.74 |
| Somnolence (n = 175, 169, 178, 171) | 23.90 ± 17.57 | 27.60 ± 18.61 | 25.50 ± 18.67 | 26.00 ± 18.77 |
| Sleep quantity (n = 175, 169, 178, 171) | 6.80 ± 1.08 | 6.50 ± 1.25 | 6.60 ± 1.16 | 6.50 ± 1.26 |
| Sleep problem index I (n = 175, 169, 178, 171) | 29.40 ± 17.26 | 35.30 ± 18.82 | 33.40 ± 16.73 | 35.00 ± 16.54 |
| Sleep problem index II (n = 175, 169, 178, 171) | 30.70 ± 17.15 | 36.60 ± 18.90 | 34.10 ± 17.05 | 36.30 ± 16.81 |
MOS-SS: Participant rated instrument to assess sleep quantity, quality; comprised of 12 items yielding 7 subscale scores: sleep disturbance, snoring, awakening short of breath/ headache, sleep adequacy, somnolence, sleep quantity, optimal sleep, 2 composite index scores: sleep problems Index I, II. Optimal sleep subscale scores range: 0-1; Optimal sleep = 1 if 'Average hours sleep' = 7 or 8, is 0 if 'Average hours sleep' is non-missing and less than 7, and is missing if 'Average hours sleep' is missing. Higher scores reflect better sleep outcomes.
| Participants | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Number of Participants With Medical Outcomes Study-Sleep Scale (MOS-SS)- Optimal Sleep at Week 12 | 84 | 64 | 77 | 68 |
POMS are participant-rated instrument comprising 6 sub-scales (tension-anxiety, depression-dejection, anger-hostility, vigor-activity, fatigue-inertia, and confusion-bewilderment) and each subscale comprising 5 items, on 'How you feel right now?' (Scale: 0=not at all, 1=a little, 2=moderately, 3=quite a bit, 4=extremely). All items were rated in the same direction except for vigor-activity. A total score is obtained for each scale. The range of total score is 0 - 100, with higher score indicating more mood disturbance.
No measurements were reported for this outcome.
RLS QoL: Participant rated instrument used to assess the impact of RLS on quality of life and health status function (symptom severity, daily activity, social functioning, sleep, concentrating and decision making, traveling, sexual activity, and work) yielding a summary score ranging from 0-100. Higher scores reflect better quality of life.
| Units on Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Restless Legs Syndrome-Quality of Life Scale (RLS-QoL) at Week 12 | 77.75 ± 10.92 | 73.33 ± 13.02 | 75.48 ± 12.69 | 73.23 ± 13.98 |
SF-36 is a standardized survey evaluating 8 aspects of functional health and well being (physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health); 2 summary scores (physical and mental component); and self evaluated change in health status (summary of health status). The score for subscale scores and 2 summary score is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning). Summary of health status is a 5-point Likert scale ranging from "0=much worse now" to "4=much better now". Higher subscale and summary score reflect better health status.
| Units on a Scale | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Physical functioning | 83.70 ± 18.30 | 81.90 ± 19.56 | 82.40 ± 19.98 | 83.00 ± 19.22 |
| Role physical | 81.20 ± 20.75 | 79.60 ± 19.37 | 79.10 ± 20.71 | 81.50 ± 19.70 |
| Bodily pain | 73.30 ± 20.51 | 65.20 ± 20.14 | 69.00 ± 20.40 | 65.50 ± 20.03 |
| General health | 73.60 ± 18.37 | 69.80 ± 18.33 | 70.50 ± 17.68 | 72.80 ± 19.47 |
| Vitality | 62.40 ± 19.27 | 59.00 ± 19.69 | 59.80 ± 20.17 | 59.30 ± 20.51 |
| Social functioning | 87.20 ± 18.01 | 84.50 ± 18.14 | 84.00 ± 18.75 | 86.80 ± 18.37 |
| Role emotional | 85.10 ± 18.91 | 83.90 ± 17.77 | 84.60 ± 18.09 | 87.00 ± 18.25 |
| Mental health | 77.40 ± 16.13 | 74.60 ± 16.80 | 76.10 ± 16.29 | 78.70 ± 15.23 |
| Summary physical score | 78.00 ± 16.50 | 74.20 ± 15.92 | 75.30 ± 16.43 | 75.70 ± 16.03 |
| Summary mental score | 78.00 ± 15.73 | 75.50 ± 15.60 | 76.10 ± 15.32 | 78.00 ± 15.76 |
| Summary of health status | 3.10 ± 0.47 | 3.10 ± 0.49 | 3.20 ± 0.54 | 3.10 ± 0.53 |
WPAI: 6 question participant rated questionnaire to determine degree to which SHP affected work productivity while at work and outside of work. Four scores are derived: percentage of absenteeism and presenteeism (reduced productivity while at work), overall work impairment score combining absenteeism and presenteeism, percentage of impairment in activities performed outside of work. Score range: 0 (not affected/no impairment) to 10 (completely affected/impaired). WPAI outcomes expressed as impairment percentages with higher numbers indicating greater impairment and less productivity.
| Percentage of impairment | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo |
|---|---|---|---|---|
| Overall work (n= 10, 7, 11, 10) | 6.00 ± 9.66 | 5.70 ± 11.34 | 9.10 ± 20.71 | 14.60 ± 23.39 |
| Activity (n= 18, 22, 25, 20) | 12.20 ± 19.27 | 20.90 ± 24.28 | 22.80 ± 23.01 | 23.00 ± 24.52 |
| Work time missed (n= 10, 7, 11, 10) | 0.00 ± 0.00 | 0.00 ± 0.00 | 0.00 ± 0.00 | 1.50 ± 3.62 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Pregabalin 300 mg | — | 9/182 (4.9%) | 134/182 (73.6%) |
| Pramipexole 0.25 mg | — | 12/178 (6.7%) | 110/178 (61.8%) |
| Pramipexole 0.5 mg | — | 9/180 (5%) | 118/180 (65.6%) |
| Placebo to Pregabalin 300 mg | — | 5/59 (8.5%) | 42/59 (71.2%) |
| Placebo to Pramipexole 0.25 mg | — | 2/59 (3.4%) | 34/59 (57.6%) |
| Placebo to Pramipexole 0.5 mg | — | 0/61 (0%) | 41/61 (67.2%) |
| Event | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo to Pregabalin 300 mg | Placebo to Pramipexole 0.25 mg | Placebo to Pramipexole 0.5 mg |
|---|---|---|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/182 | 0/178 | 0/180 | 1/59 | 0/59 | 0/61 |
| Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/182 | 0/178 | 1/180 | 1/59 | 0/59 | 0/61 |
| Cerebrovascular accidentNervous system disorders | 0/182 | 1/178 | 0/180 | 1/59 | 0/59 | 0/61 |
| Multiple sclerosisNervous system disorders | 0/182 | 0/178 | 0/180 | 0/59 | 1/59 | 0/61 |
| Suicidal ideationPsychiatric disorders | 0/182 | 0/178 | 0/180 | 1/59 | 0/59 | 0/61 |
| Withdrawal syndromePsychiatric disorders | 0/182 | 0/178 | 0/180 | 1/59 | 0/59 | 0/61 |
| Spinal deformity correctionSurgical and medical procedures | 0/182 | 0/178 | 0/180 | 0/59 | 1/59 | 0/61 |
| Chest painGeneral disorders | 0/182 | 2/178 | 0/180 | 0/59 | 0/59 | 0/61 |
| FallInjury, poisoning and procedural complications | 0/182 | 1/178 | 2/180 | 0/59 | 0/59 | 0/61 |
| Angina pectorisCardiac disorders | 0/182 | 1/178 | 0/180 | 0/59 | 0/59 | 0/61 |
| Event | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo to Pregabalin 300 mg | Placebo to Pramipexole 0.25 mg | Placebo to Pramipexole 0.5 mg |
|---|---|---|---|---|---|---|
| DizzinessNervous system disorders | 39/182 | 15/178 | 17/180 | 10/59 | 6/59 | 3/61 |
| HeadacheNervous system disorders | 22/182 | 30/178 | 35/180 | 9/59 | 6/59 | 12/61 |
| SomnolenceNervous system disorders | 32/182 | 12/178 | 14/180 | 7/59 | 4/59 | 5/61 |
| NasopharyngitisInfections and infestations | 19/182 | 20/178 | 17/180 | 3/59 | 3/59 | 9/61 |
| NauseaGastrointestinal disorders | 11/182 | 18/178 | 26/180 | 3/59 | 3/59 | 4/61 |
| InfluenzaInfections and infestations | 9/182 | 13/178 | 3/180 | 4/59 | 8/59 | 7/61 |
| FatigueGeneral disorders | 23/182 | 19/178 | 22/180 | 7/59 | 5/59 | 8/61 |
| Weight increasedInvestigations | 16/182 | 12/178 | 12/180 | 2/59 | 7/59 | 4/61 |
| ConstipationGastrointestinal disorders | 14/182 | 3/178 | 2/180 | 5/59 | 1/59 | 0/61 |
| DiarrhoeaGastrointestinal disorders | 7/182 | 9/178 | 10/180 | 2/59 | 5/59 | 5/61 |
| Age, Customized(Participants) | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo to Pregabalin 300 mg | Placebo to Pramipexole 0.25 mg | Placebo to Pramipexole 0.5 mg | Total |
|---|---|---|---|---|---|---|---|
| Less than 18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18 to 44 years | 37 | 34 | 45 | 11 | 17 | 20 | 164 |
| 45 to 64 years | 101 | 85 | 84 | 29 | 32 | 31 | 362 |
| Greater than and equal to 65 years | 44 | 59 | 51 | 19 | 10 | 10 | 193 |
| Sex: Female, Male(Participants) | Pregabalin 300 mg | Pramipexole 0.25 mg | Pramipexole 0.5 mg | Placebo to Pregabalin 300 mg | Placebo to Pramipexole 0.25 mg | Placebo to Pramipexole 0.5 mg | Total |
|---|---|---|---|---|---|---|---|
| Female | 123 | 108 | 99 | 37 | 36 | 38 | 441 |
| Male | 59 | 70 | 81 | 22 | 23 | 23 | 278 |
Showing the first 100 of 110 sites across 9 countries. Choose a country and city above to see the rest.
The record gives a start of Dec 2008, a primary completion of May 2011 and a completion of May 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Sep 2012, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2012. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pregabalin
Pfizer's Upjohn has merged with Mylan to form Viatris Inc. →